Indication intelligence, analysis and sector perception

AxoGen (AXGN) now proposes a 3 M share offering priced at $41.00 - SELL

May 9, 2018 7:43am

The offering was upsized to 3 M shares (from 2 M) and the overallottment was also increased to 450 K shares (by 150 K share)

AXGN closed up +$0.20 to $53.35 on Tuesday after Monday's $43.15 $43.15 considering 5/1's, the previous Tuesday's $38.35

With 34.68 M shares outstanding and a float of 27.82 M

AXGN has upsized a 2 M share offering to 3 M shares.

In addition, AxoGen granted the underwriters a 30-day option to purchase 450,000 shares (a 150 K share increase)old in connection with the offering at the public offering price.

Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. William Blair & Company, LLC and JMP Securities LLC are acting as co-managers.

The upsizing is a first for 2018 ...

Maintaining SELL

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 31 min ago
RegMed Investors (RMi) Closing Bell: start thinking of sector equities’ future direction without the geopolitical cloud overhead

14 hours 32 min ago
RegMed Investors’ (RMi) pre-open: Start BUYING-in after a 5-session downhill slide

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.